Genmab data points to early bone cancer drug launch: analysts

February 4, 2015 11:43 AM

3 0

COPENHAGEN (Reuters) - Positive results from a trial by Danish biotech company Genmab of its bone marrow cancer drug could lead to a launch as early as this year and it may become a blockbuster treatment earning $3.5 billion in annual revenues, analysts said.

Genmab said the study of daratumumab, which evaluated multiple myeloma patients who had already had at least three different lines of therapy unsuccessfully, showed an overall response rate of 29.2 percent.

Read more

To category page